EAACI Congress 2025
BackTPS55 - Asthma 06
Sunday 15 Jun, 12:45 PM -
13:45 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
D3.96
A Case of Herpes Zoster Following the First Dose of Benralizumab
D3.104
A step towards standardized Clinical Remission Criteria for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): insights from a real-life study
D3.110
Contribution of biotherapies in the reintroduction of NSAIDs in patients with moderate to severe asthma, hypersensitive to COX-1 inhibitor NSAIDs
D3.99
Early Real-World Outcomes of Tezepelumab in Severe Asthma Patients Unresponsive to Prior Biologics
D3.103
Impact of aspirin-induced bronchospasm on the in vitro Aspirin Hypersensitivity Diagnostic Index in the patients with Aspirin Exacerbated Respiratory Disease
D3.113
In silico system pharmacology modeling provides insights into a mechanism for greater potency of TSLP/TSLPR pathway inhibition with verekitug, a novel antibody antagonist of TSLPR, as compared to tezepelumab
D3.107
Investigating the Role of IL17 rs763780 Gene Polymorphism Associated with Asthma among Population of West Bengal, India
D3.109
Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis
D3.111
Lymphocyte profile and asthma control during the treatment with benralizumab in real life
D3.108
PTGDR2 Blood Expression as a Potential Biomarker for Predicting Super-Response to IL-5-Targeted Therapies in Severe Asthma
D3.97
Postoperative Anti-IgE Therapy for Chronic Rhinosinusitis with Nasal Polyps and Asthma: Efficacy and Prognostic Factors
D3.106
Real-World Dupilumab Effectiveness Through 18 Months in Patients with CRSwNP and Coexisting Asthma: Results from the Global AROMA Registry
D3.100
Risk Factors and Biomarkers for COVID-19 and Allergic Diseases
D3.112
Role of nasal cytology in patients with bronchial asthma
D3.105
Suspected EGPA in a patient on Dupilumab treatment: confirmed diagnosis of sarcoidosis - case report
